These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 12775533)

  • 1. Treatment of essential thrombocythemia in childhood.
    Scherer S; Ferrari R; Rister M
    Pediatr Hematol Oncol; 2003; 20(5):361-5. PubMed ID: 12775533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anagrelide in the treatment of thrombocythemia essential (ET)].
    Mazur G; Wróbel T; Podolak-Dawidziak M; Kuliszkiewicz-Janus M; Potoczek S; Nosol J; Kuliczkowski K
    Pol Arch Med Wewn; 2004 Dec; 112(6):1445-50. PubMed ID: 15962609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
    Rey J; Viallard JF; Keddad K; Smith J; Wilde P; Kiladjian JJ;
    Eur J Haematol; 2014 Feb; 92(2):127-36. PubMed ID: 24118452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
    Iványi JL; Marton É; Plander M; Szendrei T
    Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A long-term study of young patients with essential thrombocythemia treated with anagrelide.
    Mazzucconi MG; Redi R; Bernasconi S; Bizzoni L; Dragoni F; Latagliata R; Santoro C; Mandelli F
    Haematologica; 2004 Nov; 89(11):1306-13. PubMed ID: 15531452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
    Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L
    Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of essential thrombocythemia with anagrelide.
    Chintagumpala MM; Kennedy LL; Steuber CP
    J Pediatr; 1995 Sep; 127(3):495-8. PubMed ID: 7658287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of essential thrombocythemia with anagrelide: a ten-year experience].
    Kornblihtt LI; Vassallu PS; Heller P; Molinas FC
    Medicina (B Aires); 2002; 62(3):231-6. PubMed ID: 12150005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
    Cacciola RR; Di Francesco E; Pezzella F; Tibullo D; Giustolisi R; Cacciola E
    Acta Haematol; 2007; 118(4):215-8. PubMed ID: 18057866
    [No Abstract]   [Full Text] [Related]  

  • 10. [Essential thrombocythemia: therapy with anagrelide].
    Mazzucconi MG; Ferrari A; Balduini CL
    Haematologica; 1991 Jun; 76 Suppl 3():378-81. PubMed ID: 1661268
    [No Abstract]   [Full Text] [Related]  

  • 11. [Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients].
    Burkhard R; Adam H; Widmer L; Honegger HP
    Schweiz Med Wochenschr; 1998 Nov; 128(46):1808-12. PubMed ID: 9857387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anagrelide in primary thrombocythemia].
    Knutsen H; Hysing J
    Tidsskr Nor Laegeforen; 2001 May; 121(12):1478-82. PubMed ID: 11449771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.
    Birgegård G; Björkholm M; Kutti J; Lärfars G; Löfvenberg E; Markevärn B; Merup M; Palmblad J; Mauritzson N; Westin J; Samuelsson J
    Haematologica; 2004 May; 89(5):520-7. PubMed ID: 15136214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia.
    Petrides PE
    Expert Opin Pharmacother; 2004 Aug; 5(8):1781-98. PubMed ID: 15264993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Essential thrombocythemia in a child: management with anagrelide.
    Chintagumpala MM; Steuber CP; Mahoney DH; Ogden AK; Fernbach DJ
    Am J Pediatr Hematol Oncol; 1991; 13(1):52-6. PubMed ID: 2029080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of starting doses of anagrelide as a first-line therapy in patients with cytoreductive therapy-naïve essential thrombocythemia: difference between starting at 0.5 and 1.0 mg/day.
    Hashimoto Y; Ito T; Tanaka Y; Nakaya A; Fujita S; Satake A; Nakanishi T; Konishi A; Hotta M; Yoshimura H; Ishii K; Hashimoto A; Kondo T; Omura H; Shinzato I; Tanaka T; Nomura S
    Int J Hematol; 2020 Jul; 112(1):33-40. PubMed ID: 32328973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anagrelide for essential thrombocythemia.
    Med Lett Drugs Ther; 1997 Dec; 39(1016):120. PubMed ID: 9422046
    [No Abstract]   [Full Text] [Related]  

  • 18. Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis.
    Mesquita Mdo C; Sol EB; Malarme M; Noubouossie D; Demulder AC
    Clin Ther; 2009 Nov; 31(11):2559-64. PubMed ID: 20110000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful rechallenge with anagrelide in a patient with anagrelide-associated cardiomyopathy.
    Wong RS; Lam LW; Cheng G
    Ann Hematol; 2008 Aug; 87(8):683-4. PubMed ID: 18299832
    [No Abstract]   [Full Text] [Related]  

  • 20. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
    N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.